S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Gross Margin
Shenzhen Hepalink Pharmaceutical Group Co Ltd

32.8%
Current
31%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
32.8%
=
Gross Profit
1.8B
/
Revenue
5.5B

Gross Margin Across Competitors

Country CN
Market Cap 13.5B CNY
Gross Margin
33%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.99 CNY
Undervaluation 17%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
32.8%
=
Gross Profit
1.8B
/
Revenue
5.5B
What is the Gross Margin of Shenzhen Hepalink Pharmaceutical Group Co Ltd?

Based on Shenzhen Hepalink Pharmaceutical Group Co Ltd's most recent financial statements, the company has Gross Margin of 32.8%.